Joinn Laboratories (China) Co (HKSE:06127) Cash-to-Debt : 45.09 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Joinn Laboratories (China) Co's cash to debt ratio for the quarter that ended in Sep. 2024 was 45.09.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Joinn Laboratories (China) Co could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Joinn Laboratories (China) Co's Cash-to-Debt or its related term are showing as below:

HKSE:06127' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.04 Med: 54.8 Max: No Debt
Current: 45.09

During the past 12 years, Joinn Laboratories (China) Co's highest Cash to Debt Ratio was No Debt. The lowest was 1.04. And the median was 54.80.

HKSE:06127's Cash-to-Debt is ranked better than
90.71% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.99 vs HKSE:06127: 45.09

Joinn Laboratories (China) Co Cash-to-Debt Historical Data

The historical data trend for Joinn Laboratories (China) Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Joinn Laboratories (China) Co Cash-to-Debt Chart

Joinn Laboratories (China) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

13.78

5.94

50.72

37.91

46.62

Joinn Laboratories (China) Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															35.73	46.62	52.09	59.53	45.09

Competitive Comparison of Joinn Laboratories (China) Co's Cash-to-Debt

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Joinn Laboratories (China) Co's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Cash-to-Debt falls into.

Joinn Laboratories (China) Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Joinn Laboratories (China) Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3539.759	/	(30.079	+	45.857)
	=	46.62

Joinn Laboratories (China) Co's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3547.924	/	(42.608	+	36.083)
	=	45.09

Joinn Laboratories (China) Co (HKSE:06127) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Joinn Laboratories (China) Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Joinn Laboratories (China) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

603127:China

Address

A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176

Website

https://www.joinnlabs.com

Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.

Executives

Futu Trustee Limited	2301 Trustee
Ubs Group Ag	2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities	2102 Investment manager
Fil Limited	2201 Interest of corporation controlled by you
Pandanus Associates Inc.	2201 Interest of corporation controlled by you
Pandanus Partners L.p.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Fidelity Funds	2101 Beneficial owner
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc	2101 Beneficial owner
Morgan Stanley	2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Apg Asset Management N.v.	2101 Beneficial owner
Apg Groep N.v.	2101 Beneficial owner
Stichting Pensioenfonds Abp	2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines